-
Je něco špatně v tomto záznamu ?
EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma
M. Jerkeman, I. Aurer, E. Campo, CY. Cheah, J. Clark, J. Doorduijn, TA. Eyre, M. Fehr, E. Giné, M. Gomes da Silva, P. Klener, M. Ladetto, V. Ribrag, O. Shpilberg, J. Walewski, M. Dreyling, EHA Guidelines Committee and the European MCL Network
Status neindexováno Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2017
PubMed Central
od 2017
Europe PubMed Central
od 2017
ProQuest Central
od 2024-01-01
Wiley Free Content
od 2017
Wiley-Blackwell Open Access Titles
od 1997
ROAD: Directory of Open Access Scholarly Resources
od 2017
PubMed
41132246
DOI
10.1002/hem3.70233
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Mantle cell lymphoma (MCL) is a relatively rare B-cell lymphoma subtype, with a higher incidence among males and a median age of 70 years at diagnosis. MCL is characterized by clinically diverse behavior, from indolent disease to extremely aggressive, related to the presence of biological risk factors such as proliferation rate and TP53 mutations. Most often, patients present with disseminated disease, necessitating systemic treatment. Immunochemotherapy has historically been the mainstay of treatment, but recent data indicate that addition of novel agents, especially covalent Bruton tyrosine kinase inhibitors (cBTKi), may substantially improve outcome in younger and older patients, although a curative approach remains to be shown. In elderly patients, the standard of care is still immuno-chemotherapy such as rituximab-bendamustine, although this may be challenged by non-chemotherapeutic options, such as rituximab plus cBTKi. For patients with relapsed or refractory disease, treatment options are developing rapidly, including CAR-T cell therapy, novel BTK targeting agents, BCL2 inhibitors, and T-cell engagers. In this clinical practice guideline, we present current evidence-based recommendations for diagnosis, staging, treatment, and follow-up of MCL.
Department of Hematology Portuguese Institute of Oncology Lisbon Portugal
Department of Hematology Sir Charles Gairdner Hospital Perth Western Australia Australia
Department of Lymphoid Malignancies European Reference Network EuroBloodNet Warsaw Poland
Department of Medical Oncology and Hematology Cantonal Hospital St Gallen St Gallen Switzerland
Department of Medicine 3 LMU University Hospital Munich
Department of Oncology Skåne University Hospital Lund Sweden
Haematology and Cancer Centre Oxford University Hospitals NHS Foundation Trust Oxford United Kingdom
Hematology Department Assuta Medical Center Tel Aviv Israel
Inspire2Live Loosdrecht The Netherlands
Institut de Cancérologie Gustave Roussy Villejuif France
SCDU Ematologia Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Alessandria Italy
University Hospital Centre Zagreb and Medical School University of Zagreb Zagreb Croatia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc26002109
- 003
- CZ-PrNML
- 005
- 20260122082730.0
- 007
- ta
- 008
- 260116s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/hem3.70233 $2 doi
- 035 __
- $a (PubMed)41132246
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Jerkeman, Mats $u Department of Oncology Skåne University Hospital Lund Sweden $u Lund University Lund Sweden $1 https://orcid.org/0000000345096707
- 245 10
- $a EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma / $c M. Jerkeman, I. Aurer, E. Campo, CY. Cheah, J. Clark, J. Doorduijn, TA. Eyre, M. Fehr, E. Giné, M. Gomes da Silva, P. Klener, M. Ladetto, V. Ribrag, O. Shpilberg, J. Walewski, M. Dreyling, EHA Guidelines Committee and the European MCL Network
- 520 9_
- $a Mantle cell lymphoma (MCL) is a relatively rare B-cell lymphoma subtype, with a higher incidence among males and a median age of 70 years at diagnosis. MCL is characterized by clinically diverse behavior, from indolent disease to extremely aggressive, related to the presence of biological risk factors such as proliferation rate and TP53 mutations. Most often, patients present with disseminated disease, necessitating systemic treatment. Immunochemotherapy has historically been the mainstay of treatment, but recent data indicate that addition of novel agents, especially covalent Bruton tyrosine kinase inhibitors (cBTKi), may substantially improve outcome in younger and older patients, although a curative approach remains to be shown. In elderly patients, the standard of care is still immuno-chemotherapy such as rituximab-bendamustine, although this may be challenged by non-chemotherapeutic options, such as rituximab plus cBTKi. For patients with relapsed or refractory disease, treatment options are developing rapidly, including CAR-T cell therapy, novel BTK targeting agents, BCL2 inhibitors, and T-cell engagers. In this clinical practice guideline, we present current evidence-based recommendations for diagnosis, staging, treatment, and follow-up of MCL.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Aurer, Igor $u University Hospital Centre Zagreb and Medical School, University of Zagreb Zagreb Croatia
- 700 1_
- $a Campo, Elias $u Department of Pathology, Hospital Clínic de Barcelona Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), University of Barcelona, CIBERONC Barcelona Spain
- 700 1_
- $a Cheah, Chan Y $u Department of Hematology Sir Charles Gairdner Hospital Perth Western Australia Australia
- 700 1_
- $a Clark, Jonathan $u Inspire2Live Loosdrecht The Netherlands $1 https://orcid.org/0000000195519662
- 700 1_
- $a Doorduijn, Jeanette $u Department of Hematology, Erasmus MC Cancer Institute University Medical Center Rotterdam The Netherlands
- 700 1_
- $a Eyre, Toby A $u Haematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust Oxford United Kingdom
- 700 1_
- $a Fehr, Martin $u Department of Medical Oncology and Hematology Cantonal Hospital St Gallen St. Gallen Switzerland
- 700 1_
- $a Giné, Eva $u Hematology Department, Hospital Clínic of Barcelona Institute of Biomedical Research August Pi i Sunyer (IDIBAPS), CIBERONC Barcelona Spain
- 700 1_
- $a Gomes da Silva, Maria $u Department of Hematology Portuguese Institute of Oncology Lisbon Portugal
- 700 1_
- $a Klener, Pavel $u First Dept. Of Internal Medicine-Hematology University General Hospital Prague and First Faculty of Medicine, Charles University Prague Czech Republic
- 700 1_
- $a Ladetto, Marco $u Department of Translational Medicine Division of Hematology, University of Eastern Piedmont Alessandria Italy $u SCDU Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Alessandria Italy
- 700 1_
- $a Ribrag, Vincent $u Institut de Cancérologie Gustave Roussy Villejuif France
- 700 1_
- $a Shpilberg, Ofer $u Hematology Department Assuta Medical Center Tel-Aviv Israel
- 700 1_
- $a Walewski, Jan $u Department of Lymphoid Malignancies Maria Sklodowska-Curie National Research Institute of Oncology Warsaw $u Department of Lymphoid Malignancies European Reference Network/EuroBloodNet Warsaw Poland
- 700 1_
- $a Dreyling, Martin $u Department of Medicine III LMU University Hospital Munich
- 710 2_
- $a EHA Guidelines Committee and the European MCL Network
- 773 0_
- $w MED00201259 $t HemaSphere $x 2572-9241 $g Roč. 9, č. 10 (2025), s. e70233
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/41132246 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20260116 $b ABA008
- 991 __
- $a 20260122082715 $b ABA008
- 999 __
- $a ok $b bmc $g 2470379 $s 1267826
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2025 $b 9 $c 10 $d e70233 $e 20251022 $i 2572-9241 $m HemaSphere $n Hemasphere $x MED00201259
- LZP __
- $a Pubmed-20260116
